Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MLN1117

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug MLN1117?

MLN1117 is an investigational drug.

There have been 8 clinical trials for MLN1117. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Neoplasms, Endometrial Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., Avera McKennan Hospital & University Health Center, and European Network of Translational Research in Ovarian Cancer - EUTROC.

There are four US patents protecting this investigational drug and sixty-three international patents.

Recent Clinical Trials for MLN1117
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsAvera McKennan Hospital & University Health CenterPhase 1
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaMillennium Pharmaceuticals, Inc.Phase 2
Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial CancerEuropean Network of Individualized Treatment in Endometrial Cancer - ENITECPhase 2

See all MLN1117 clinical trials

Clinical Trial Summary for MLN1117

Top disease conditions for MLN1117
Top clinical trial sponsors for MLN1117

See all MLN1117 clinical trials

US Patents for MLN1117

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MLN1117   Start Trial Heterocyclic compounds and uses thereof INTELLIKINE, INC. (La Jolla, CA)   Start Trial
MLN1117   Start Trial Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof Intellikine LLC (La Jolla, CA)   Start Trial
MLN1117   Start Trial Kinase inhibitor polymorphs Intellikine LLC (La Jolla, CA) Sigma-Aldrich Company Limited (GB)   Start Trial
MLN1117   Start Trial Combination of kinase inhibitors and uses thereof Intellikine LLC (La Jolla, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MLN1117

Drugname Country Document Number Estimated Expiration Related US Patent
MLN1117 Australia 2010284254 2029-08-17   Start Trial
MLN1117 Brazil 112012003709 2029-08-17   Start Trial
MLN1117 Canada 2771532 2029-08-17   Start Trial
MLN1117 China 102573846 2029-08-17   Start Trial
MLN1117 China 105078978 2029-08-17   Start Trial
MLN1117 Colombia 6612213 2029-08-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.